NCT02785172View on ClinicalTrials.gov

Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

January 31, 2017

Conditions
Psoriasis
Interventions
DRUG

IDP-118 Vehicle Lotion

Vehicle

DRUG

IDP-118 Vehicle Cream

Vehicle

DRUG

IDP-118 Lotion

Lotion

DRUG

Ultravate Cream

Cream

Trial Locations (14)

27514

Valeant Site 08, Chapel Hill

29464

Valeant Site 13, Mt. Pleasant

33111

Valeant Site 02, Miami

33313

Valeant Site 05, Lauderdale Lakes

43085

Valeant Site 06, Columbus

55421

Valeant Site 07, Fridley

77449

Valeant Site 11, Katy

77479

Valeant Site 01, Sugar Land

78201

Valeant Site 10, San Antonio

84103

Valeant Site 14, Salt Lake City

91941

Valeant Site 04, La Mesa

92093

Valeant Site 03, San Diego

Valeant Site 09, San Diego

92831

Valeant Site 12, Fullerton

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT02785172 - Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis | Biotech Hunter | Biotech Hunter